Alpha Signal Monitor - Daily Market Briefing | March 23, 2026
Daily Market Research Report
March 23, 2026
Alpha Signal Monitor
Welcome to your daily pre-market briefing. This report provides key insights on market opportunities and analyst perspectives to help identify potential alpha signals.
Today's Coverage: - Gold ETF Outlook: Institutional perspectives on gold-backed ETFs - Stock Ratings: Latest analyst ratings and target prices for our watchlist - IPO Calendar: Upcoming initial public offerings and market debuts
Watchlist Stocks: AAPL, MSFT, GOOGL, AMZN, NVDA, META, TSLA, AVGO, TSM
This report is generated using advanced AI research capabilities with real-time market data access.
Institutional Outlook on Gold ETFs (as of March 23, 2026)
Trading Idea: Buy Rationale (TL;DR): Most leading houses (GS, JPM, BofA, UBS, DB, MS) project higher gold into late-2026, with several $5,000–$6,200/oz targets; only Citi is meaningfully bearish. Physical-gold ETFs (GLD, IAU, BAR) should track this upside while offering liquidity and custody simplicity.
Drivers cited across institutions include continued central-bank diversification, renewed ETF inflows as rate cuts lower real yields, elevated fiscal deficits and geopolitics, and a weaker-to-stable USD. While 2026 may be volatile, the balance of institutional guidance still skews bullish for spot gold and thus for GLD/IAU/BAR. (ubs.com)
Key Drivers - Central-bank buying remains a structural bid for gold and is expected to persist into 2026. - ETF inflows likely to accelerate if real yields fall with Fed easing. - Geopolitical risk premium (conflict/tariffs) and fiscal deficits support portfolio hedging demand. - Limited mine supply growth and permitting constraints curb supply response. - Diversification by private investors and EM reserve managers broadens the buyer base.
| Institution | Stance | Price View | Key Evidence | Last Update | Source |
|---|---|---|---|---|---|
| Goldman Sachs | Bullish | Raised end‑2026 gold forecast to USD 5,400/oz (from 4,900). | Upgrade driven by stronger private‑sector allocation and continued EM central‑bank diversification into gold. | January 22, 2026 | (economictimes.indiatimes.com) |
| Morgan Stanley | Constructive/Bullish | USD 4,400/oz by end‑2026 (up from ~USD 3,313 prior). | Sees rally continuing on weaker USD, ETF inflows, and ongoing central‑bank demand; flags possible demand destruction at very high prices. | October 22, 2025 | (morganstanley.com) |
| JP Morgan | Overweight/Bullish | Average USD 5,055/oz in Q4‑2026; ‘highest conviction long.’ | Forecast underpinned by robust investor demand (incl. ETF inflows) and steady central‑bank buying. | October 23, 2025 | (jpmorgan.com) |
| Bank of America | Bullish | Targets USD 6,000/oz by Spring 2026 (after prior USD 5,000 2026 call). | BofA’s metals research cites persistent macro drivers; expects the bull market to extend though acknowledges volatility. | January 23, 2026 | (kitco.com) |
| Citigroup | Bearish/Underweight | Sees gold falling to USD 2,500–2,700/oz by H2‑2026; below USD 3,000 in coming quarters. | Anticipates weaker investment demand as growth improves and Fed cuts reduce risk premia. | June 17, 2025 | (bloomberg.com) |
| UBS | Most Preferred/Bullish | USD 6,200/oz for Mar/Jun/Sep 2026; YE‑2026 baseline USD 4,800/oz (prior USD 5,000 mid‑year path). | UBS CIO raised near‑term 2026 targets on heavy investment flows and central‑bank demand; year‑end base case remains below peak with volatility expected. | January 29, 2026 | (ubs.com) |
| HSBC | Neutral to Positive (with high volatility) | 2026 average ~USD 4,587/oz; upside risk to USD 5,000/oz (H1‑2026). | Warns that easing geopolitical risks or a pause in Fed cuts could spark a sharper pullback; otherwise sees elevated levels sustained. | January 8, 2026 | (investinglive.com) |
| Deutsche Bank | Constructive/Bullish | 2026 average USD 4,450/oz (from USD 4,000); cites $3,950–$4,950 trading range. | Upgrade reflects stabilizing investor flows and persistent official‑sector demand. | November 26, 2025 | (investing.com) |
Risk Considerations - Faster Fed re-tightening or a renewed rise in real yields could pressure gold and trigger ETF outflows. - Geopolitical de-escalation and stronger global growth could compress the risk premium. - A stronger USD could cap upside in non-USD demand. - If central-bank purchases slow materially or turn to net sales, the structural bid could weaken. - High prices risk demand destruction in jewelry and price-sensitive segments, amplifying volatility.
Maintain Buy on GLD/IAU/BAR with a buy‑the‑dip discipline into 2026. Favor lower‑fee wrappers (IAU/BAR) for core exposure; GLD for superior liquidity. Expect intermittent pullbacks amid policy and geopolitical headlines, but net‑higher highs if central‑bank and ETF demand persist.
Stock Ratings — U.S. Big-Bank Tech Stock Ratings & Target Prices (as of March 23, 2026)
Below is a structured summary of the latest publicly reported ratings/targets from Goldman Sachs (GS), Morgan Stanley (MS), JPMorgan (JPM), Bank of America (BAC), Citigroup (C), and Wells Fargo (WFC) for the requested stocks. Primary bank PDFs are typically paywalled; where applicable, we cite MarketBeat issuer pages that record each bank’s most recent published action. Targets and dates reflect the latest visible entries on those pages. Ratings use the bank’s own terminology (e.g., Overweight/Equal Weight/Underweight).
AAPL - Apple Inc.
Most large banks remain constructive into the 2026 product/AI cycle; recent JPM target hike offsets earlier trims from other brokers.
| Institution | Rating | Target Price | Last Update | Notes | Source |
|---|---|---|---|---|---|
| Goldman Sachs | Buy | - | 2026-03-02 | Reiterated rating; latest target not shown on public page. | https://www.marketbeat.com/stocks/NASDAQ/AAPL/forecast/ |
| Morgan Stanley | Overweight | $315 | 2025-12-05 | Target raised from $305 to $315. | https://www.marketbeat.com/stocks/NASDAQ/AAPL/forecast/ |
| JP Morgan | Overweight | $325 | 2026-01-30 | Target raised from $315 to $325. | https://www.marketbeat.com/stocks/NASDAQ/AAPL/forecast/ |
| Bank of America | Buy | $260 | 2024-06-14 | Older visible entry; more recent BAC note not publicly shown on page. | https://www.marketbeat.com/stocks/NASDAQ/AAPL/forecast/ |
| Citigroup | - | - | - | No recent Citi entry visible on public page. | https://www.marketbeat.com/stocks/NASDAQ/AAPL/forecast/ |
| Wells Fargo | Overweight | $300 | 2025-10-31 | Target raised from $290 to $300. | https://www.marketbeat.com/stocks/NASDAQ/AAPL/forecast/ |
Consensus View - Rating: Buy, Target Price: $300 - Consensus derived from available targets (JPM, MS, WFC, BAC).
MSFT - Microsoft Corp.
Across banks, targets were trimmed in late Jan 2026 on AI CapEx concerns, but ratings largely remain Buy/OW.
| Institution | Rating | Target Price | Last Update | Notes | Source |
|---|---|---|---|---|---|
| Goldman Sachs | Buy | - | 2026-02-09 | Reiterated Buy; target not shown on visible entry. | https://www.marketbeat.com/stocks/NASDAQ/MSFT/forecast/ |
| Morgan Stanley | Overweight | - | 2026-01-29 | Reiterated Overweight; recent target not shown on visible entry. | https://www.marketbeat.com/stocks/NASDAQ/MSFT/forecast/ |
| JP Morgan | Overweight | $550 | 2026-01-29 | Target lowered from $575 to $550. | https://www.marketbeat.com/stocks/NASDAQ/MSFT/forecast/ |
| Bank of America | Buy | $520 | 2026-01-22 | Target lowered from $640 to $520. | https://www.marketbeat.com/stocks/NASDAQ/MSFT/forecast/ |
| Citigroup | Buy | $635 | 2026-01-29 | Target lowered from $660 to $635. | https://www.marketbeat.com/stocks/NASDAQ/MSFT/forecast/ |
| Wells Fargo | Overweight | $615 | 2026-01-29 | Target lowered from $630 to $615. | https://www.marketbeat.com/stocks/NASDAQ/MSFT/forecast/ |
Consensus View - Rating: Buy, Target Price: $580 - Average of BAC, JPM, C, WFC targets visible.
GOOGL - Alphabet Inc.
Multiple banks lifted targets into Feb 2026 following Search/Cloud momentum; Wells remains at Equal Weight with a small bump.
| Institution | Rating | Target Price | Last Update | Notes | Source |
|---|---|---|---|---|---|
| Goldman Sachs | Buy | $375 | 2026-01-13 | Target raised from $330 to $375. | https://www.marketbeat.com/stocks/NASDAQ/GOOGL/forecast/ |
| Morgan Stanley | Overweight | $330 | 2025-10-30 | Target raised from $270 to $330. | https://www.marketbeat.com/stocks/NASDAQ/GOOGL/forecast/ |
| JP Morgan | Buy | - | 2026-02-06 | Reiterated Buy; target not shown on visible entry. | https://www.marketbeat.com/stocks/NASDAQ/GOOGL/forecast/ |
| Bank of America | Buy | $370 | 2025-12-02 | Target raised from $335 to $370. | https://www.marketbeat.com/stocks/NASDAQ/GOOGL/forecast/ |
| Citigroup | Buy | $390 | 2026-02-06 | Target raised from $350 to $390. | https://www.marketbeat.com/stocks/NASDAQ/GOOGL/forecast/ |
| Wells Fargo | Equal Weight | $354 | 2026-02-05 | Target raised from $350 to $354; rating Equal Weight. | https://www.marketbeat.com/stocks/NASDAQ/GOOGL/forecast/ |
Consensus View - Rating: Buy, Target Price: $364 - Average of GS, MS, BAC, C, WFC targets visible.
AMZN - Amazon.com Inc.
Broadly positive stance; mixed trims/raises around early Feb 2026 post-earnings.
| Institution | Rating | Target Price | Last Update | Notes | Source |
|---|---|---|---|---|---|
| Goldman Sachs | Buy | $300 | 2026-01-01 | Target raised from $290 to $300. | https://www.marketbeat.com/stocks/NASDAQ/AMZN/forecast/ |
| Morgan Stanley | Overweight | $300 | 2026-02-06 | Target reduced from $315 to $300. | https://www.marketbeat.com/stocks/NASDAQ/AMZN/forecast/ |
| JP Morgan | Buy | $325 | 2026-02-06 | Reiterated Buy with $325 target. | https://www.marketbeat.com/stocks/NASDAQ/AMZN/forecast/ |
| Bank of America | Buy | $286 | 2026-01-26 | Target lowered from $303 to $286. | https://www.marketbeat.com/stocks/NASDAQ/AMZN/forecast/ |
| Citigroup | Buy | - | 2026-03-17 | Reiterated Buy; target not shown on visible entry. | https://www.marketbeat.com/stocks/NASDAQ/AMZN/forecast/ |
| Wells Fargo | Overweight | $304 | 2026-02-12 | Target adjusted from $305 to $304. | https://www.marketbeat.com/stocks/NASDAQ/AMZN/forecast/ |
Consensus View - Rating: Buy, Target Price: $303 - Average of GS, MS, JPM, BAC, WFC.
NVDA - NVIDIA Corp.
Banks broadly lifted targets in late Feb 2026 on continuing AI demand; consensus remains strongly positive.
| Institution | Rating | Target Price | Last Update | Notes | Source |
|---|---|---|---|---|---|
| Goldman Sachs | Buy | $300 | 2026-02-25 | Target raised from $275 to $300. | https://www.marketbeat.com/stocks/NASDAQ/NVDA/forecast/ |
| Morgan Stanley | - | $260 | 2026-02-27 | Target set; rating not shown on visible entry (historically Overweight). | https://www.marketbeat.com/stocks/NASDAQ/NVDA/forecast/ |
| JP Morgan | Overweight | $265 | 2026-02-26 | Target raised from $250 to $265. | https://www.marketbeat.com/stocks/NASDAQ/NVDA/forecast/ |
| Bank of America | Buy | $300 | 2026-02-25 | Target raised from $275 to $300. | https://www.marketbeat.com/stocks/NASDAQ/NVDA/forecast/ |
| Citigroup | Buy | $300 | 2026-02-26 | Target raised from $270 to $300. | https://www.marketbeat.com/stocks/NASDAQ/NVDA/forecast/ |
| Wells Fargo | Overweight | - | 2025-11-28 | Reiterated Overweight; target not shown on visible entry. | https://www.marketbeat.com/stocks/NASDAQ/NVDA/forecast/ |
Consensus View - Rating: Buy, Target Price: $285 - Average of GS, MS, JPM, BAC, C where targets are visible.
META - Meta Platforms Inc.
Post-Q4 2025 updates saw broad target raises; banks remain positive on 2026/27 ad and AI monetization.
| Institution | Rating | Target Price | Last Update | Notes | Source |
|---|---|---|---|---|---|
| Goldman Sachs | Buy | - | 2025-08-05 | Reiterated Buy; target not shown on visible entry. | https://www.marketbeat.com/stocks/NASDAQ/META/forecast/ |
| Morgan Stanley | Overweight | $825 | 2026-01-29 | Target raised from $750 to $825. | https://www.marketbeat.com/stocks/NASDAQ/META/forecast/ |
| JP Morgan | - | - | - | Recent JPM entry not fully shown on visible page. | https://www.marketbeat.com/stocks/NASDAQ/META/forecast/ |
| Bank of America | Buy | $885 | 2026-01-29 | Target raised from $810 to $885. | https://www.marketbeat.com/stocks/NASDAQ/META/forecast/ |
| Citigroup | Outperform | - | 2026-01-29 | Reiterated rating; target not shown on visible entry. | https://www.marketbeat.com/stocks/NASDAQ/META/forecast/ |
| Wells Fargo | Overweight | $856 | 2026-02-02 | Target raised from $849 to $856. | https://www.marketbeat.com/stocks/NASDAQ/META/forecast/ |
Consensus View - Rating: Buy, Target Price: $855 - Average of BAC, MS, WFC targets visible.
TSLA - Tesla Inc.
Views remain polarized; 2026 brought fresh initiation from BAC (Buy) while JPM and WFC remain Underweight; MS/GS neutral-to-mixed.
| Institution | Rating | Target Price | Last Update | Notes | Source |
|---|---|---|---|---|---|
| Goldman Sachs | Neutral | $405 | 2026-01-29 | Reiterated Neutral with $405 target. | https://www.marketbeat.com/stocks/NASDAQ/TSLA/forecast/ |
| Morgan Stanley | Equal Weight | $415 | 2026-01-29 | Target reduced from $425 to $415. | https://www.marketbeat.com/stocks/NASDAQ/TSLA/forecast/ |
| JP Morgan | Underweight | $145 | 2026-01-29 | Target lowered from $150 to $145. | https://www.marketbeat.com/stocks/NASDAQ/TSLA/forecast/ |
| Bank of America | Buy | $460 | 2026-03-04 | Initiated coverage with Buy and $460 target. | https://www.marketbeat.com/stocks/NASDAQ/TSLA/forecast/ |
| Citigroup | - | - | - | No recent Citi entry visible on public page. | https://www.marketbeat.com/stocks/NASDAQ/TSLA/forecast/ |
| Wells Fargo | Underweight | $125 | 2026-01-29 | Target lowered from $130 to $125. | https://www.marketbeat.com/stocks/NASDAQ/TSLA/forecast/ |
Consensus View - Rating: Hold, Target Price: $310 - Average of GS, MS, JPM, BAC, WFC targets visible; ratings are mixed.
AVGO - AVGO Corp.
Early March 2026 saw multiple target moves; JPM and MS raised while BAC trimmed but stayed Buy.
| Institution | Rating | Target Price | Last Update | Notes | Source |
|---|---|---|---|---|---|
| Goldman Sachs | - | - | - | No recent GS entry visible on public page. | https://www.marketbeat.com/stocks/NASDAQ/AVGO/forecast/ |
| Morgan Stanley | Overweight | $470 | 2026-03-05 | Target raised from $462 to $470. | https://www.marketbeat.com/stocks/NASDAQ/AVGO/forecast/ |
| JP Morgan | Overweight | $500 | 2026-03-05 | Target raised from $475 to $500. | https://www.marketbeat.com/stocks/NASDAQ/AVGO/forecast/ |
| Bank of America | Buy | $450 | 2026-03-05 | Target lowered from $500 to $450. | https://www.marketbeat.com/stocks/NASDAQ/AVGO/forecast/ |
| Citigroup | Buy | $475 | 2026-03-05 | Target raised from $458 to $475. | https://www.marketbeat.com/stocks/NASDAQ/AVGO/forecast/ |
| Wells Fargo | - | - | - | No recent WFC entry visible on public page. | https://www.marketbeat.com/stocks/NASDAQ/AVGO/forecast/ |
Consensus View - Rating: Buy, Target Price: $474 - Average of MS, JPM, BAC, C targets visible.
TSM - TSM Corp.
Limited big-bank detail visible publicly; Citi and GS both reiterated Buy in early 2026.
| Institution | Rating | Target Price | Last Update | Notes | Source |
|---|---|---|---|---|---|
| Goldman Sachs | Buy | - | 2026-01-02 | Reiterated Buy; target not shown on visible entry. | https://www.marketbeat.com/stocks/NYSE/TSM/forecast/ |
| Morgan Stanley | - | - | - | No recent MS entry visible on public page. | https://www.marketbeat.com/stocks/NYSE/TSM/forecast/ |
| JP Morgan | - | - | - | No recent JPM entry visible on public page. | https://www.marketbeat.com/stocks/NYSE/TSM/forecast/ |
| Bank of America | - | - | - | No recent BAC entry visible on public page. | https://www.marketbeat.com/stocks/NYSE/TSM/forecast/ |
| Citigroup | Buy | - | 2026-01-05 | Reiterated Buy; target not shown on visible entry. | https://www.marketbeat.com/stocks/NYSE/TSM/forecast/ |
| Wells Fargo | - | - | - | No recent WFC entry visible on public page. | https://www.marketbeat.com/stocks/NYSE/TSM/forecast/ |
Consensus View - Rating: Buy - Consensus rating reflects available Buy reiterations; insufficient public targets to compute average.
Highlights
- NVDA: Broad-based raises late Feb 2026 (GS/C/BAC to $300; JPM to $265).
- GOOGL: GS to $375 (Jan 13, 2026); Citi to $390 (Feb 6, 2026); WFC Equal Weight to $354 (Feb 5, 2026).
- AMZN: JPM Buy $325 (Feb 6, 2026); MS OW $300 (Feb 6, 2026); GS Buy $300 (Jan 1, 2026).
- MSFT: BAC to $520 (Jan 22, 2026); JPM to $550 (Jan 29, 2026); WFC to $615 (Jan 29, 2026).
- TSLA: BAC initiates Buy $460 (Mar 4, 2026); JPM Underweight $145; WFC Underweight $125 (both Jan 29, 2026).
- AVGO: JPM to $500; MS to $470; C to $475; BAC to $450 (all Mar 5, 2026).
Notes: 1) Targets/ratings shown are the latest entries publicly visible on each MarketBeat issuer page on March 23, 2026; primary bank research PDFs are typically behind client paywalls. 2) Where a bank’s latest rating lacked a visible target on the page, target_price is null. 3) Consensus is computed from the available bank targets listed for each stock; when too few targets were visible, only a consensus rating (or null) is provided.
IPO Calendar
Timeframe: March 23, 2026 to April 23, 2026 (US equity markets)
The next month’s US IPO calendar is thin. One operating-company IPO (Salspera) and one direct listing (The Metals Royalty Company) are on the near-term docket, with few additional deals scheduled beyond this week. Geopolitical volatility and risk-off equity conditions have kept many issuers on the sidelines; recent week-ahead commentary notes just these two US listings, and broader dealmakers describe the near-term calendar as sparse. Larger, newly filed names (e.g., Pershing Square) expand the medium‑term pipeline but are unlikely to price within the next 30 days. Expect continued concentration in health care and small‑cap offerings, along with selective alternative pathways (direct listings). (renaissancecapital.com)
Salspera, Inc. (TKVA)
- Price range: $14.00 – $16.00 (preliminary)
- Shares offered: 5,666,666 primary shares (+45‑day option for 850,000 additional shares)
- Exchange: Nasdaq Stock Market (applied)
- Lead underwriters: Kingswood Capital Partners, LLC (sole book‑running manager)
- Business summary: Clinical‑stage immuno‑oncology company developing “live biopharmaceuticals,” genetically modified bacteria designed to express anti‑tumoral agents within the tumor microenvironment. Lead candidate Saltikva (attenuated Salmonella typhimurium engineered to express IL‑2) is orally administered and is advancing toward a pivotal Phase 3 trial in metastatic pancreatic cancer. (sec.gov)
- Notes: Deal terms set; timing remains subject to SEC effectiveness and Nasdaq listing approval. Renaissance Capital lists the deal on the week‑ahead calendar but does not show a firm trade date. Use of proceeds includes funding Saltikva Phase 3, additional programs, and working capital. (renaissancecapital.com)
- Sources: SEC EDGAR — S-1/A filed March 10, 2026 (Reg. No. 333-293121), SEC EDGAR — Free Writing Prospectus (March 2026), Renaissance Capital — Salspera profile and US IPO Week Ahead (Mar 20, 2026)
The Metals Royalty Company Inc. (TMCR)
- Shares offered: N/A (direct listing); company discloses 55,061,113 common shares outstanding upon completion of the direct listing
- Exchange: Nasdaq Capital Market (applied)
- Business summary: Royalty and streaming company focused on critical minerals. Post‑spinout, its sole asset is a 2.0% gross overriding royalty on the NORI polymetallic nodule project in the Clarion‑Clipperton Zone being developed by The Metals Company; the royalty is not yet producing revenue. Listing will be via a direct listing (no underwriters); Stifel is designated financial advisor for the Nasdaq opening process under Rule 4120(c)(8). (sec.gov)
- Notes: Proposed direct listing; no IPO price or primary share sale. Company expects trading to begin on or about March (date TBA), subject to Nasdaq approval and satisfaction of conditions, including release of subscription receipt proceeds by March 31, 2026. Renaissance Capital includes TMCR on the US week‑ahead calendar. (sec.gov)
- Sources: SEC EDGAR — Form F‑1 filed Feb 27, 2026 (TMCR), Nasdaq press release announcing public filing for proposed direct listing (Mar 2, 2026), Renaissance Capital — US IPO Week Ahead (Mar 20, 2026)
IPO calendars change quickly. Dates, sizes, tickers, exchanges, and syndicate roles may shift or be withdrawn prior to pricing/listing. Direct listings do not set an IPO price, and issuers receive no primary proceeds. Verify final prospectuses and exchange notices closer to the expected trade date. (renaissancecapital.com)
Sources
- Stock Ratings: https://www.marketbeat.com/stocks/NASDAQ/AAPL/forecast/, https://www.marketbeat.com/stocks/NASDAQ/AMZN/forecast/, https://www.marketbeat.com/stocks/NASDAQ/AVGO/forecast/, https://www.marketbeat.com/stocks/NASDAQ/GOOGL/forecast/, https://www.marketbeat.com/stocks/NASDAQ/META/forecast/, https://www.marketbeat.com/stocks/NASDAQ/MSFT/forecast/, https://www.marketbeat.com/stocks/NASDAQ/NVDA/forecast/, https://www.marketbeat.com/stocks/NASDAQ/TSLA/forecast/, https://www.marketbeat.com/stocks/NYSE/TSM/forecast/
- IPO Calendar: https://www.renaissancecapital.com/IPO-Center/News/117815/US-IPO-Week-Ahead-Two-deals-on-the-calendar-as-geopolitical-volatility-cont, https://www.sec.gov/Archives/edgar/data/0002087398/000110465926021062/tm2526563-10_f1.htm, https://www.sec.gov/Archives/edgar/data/2084032/000121390026025748/ea0256863-08.htm
Disclaimer
This research report is for informational purposes only and does not constitute investment advice. All information is sourced from publicly available data and should be verified independently. Past performance does not guarantee future results.
Generated on: 2026-03-23 at 11:47 UTC
Source: Alpha Signal Monitor - Automated Research System
Contact: For questions about this report, please contact your Alpha Signal Monitor administrator.
Powered by Alpha Signal Monitor | Market Intelligence Through AI